PTOV1

Across TCGA pan-cancer cohorts, PTOV1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PTOV1 data layer compared with 27 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher PTOV1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PTOV1 expression acts as an unfavorable survival marker.

CESC, STAD, and SARC are the cancer types where PTOV1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	II,III,IV	0.132	0.829	<.001	12	view →
STAD	DFS	Median	All	0.279	0.713	.009	9	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
SKCM	DFS	Median	III,IV	0.063	0.648	.003	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PTOV1–CESC (OS)

Open the CESC breakdown →